Answers are grounded in this paper and cite their sources.
Observational study examines lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma, indicating immune fitness shapes clinical response.
Bispecific antibodies (bsAbs) targeting B-cell maturation antigen (BCMA) and G protein–coupled receptor class C group 5 member D (GPRC5D) have become important therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM), producing overall response rates of up to 70% [ 1 , 2 , 3 , 4 ]. Despite these advances, clinical outcomes remain heterogeneous, and because bsAbs rely on sustained engagement of immune effector cells, treatment efficacy is dependent on the fitness of the immune compartment. As a result, readily available immune biomarkers, such as absolute lymphocyte count (ALC) and lymphocyte subset composition-, including CD4 and CD8 T cells, B cells, and natural killer (NK) cells—may capture qualitative differences in immune competence that influence the likelihood of response to bsAb therapy [ 5 ]. While studies of CAR-T therapies in RRMM have shown that baseline lymphopenia and impaired lymphocyte expansion correlate with adverse clinical outcomes [ 6 , 7 ], the prognostic impact of lymphocyte dynamics during bsAb therapy remains unclear.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: